HeartBeam (NASDAQ:BEAT) Posts Earnings Results, Misses Expectations By $0.01 EPS

HeartBeam (NASDAQ:BEAT) issued its quarterly earnings results on Thursday. The medical research company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01), FiscalAI reports. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.15 million.

Here are the key takeaways from HeartBeam’s conference call:

• Heart attack detection regulatory progress: HeartBeam submitted an FDA pre-submission for a 510(k) pathway on the AIMIGo heart attack detection indication and expects FDA feedback within 75 days. Management said a pivotal trial could potentially begin before year-end, although the required size and design remain uncertain.
• Clinical studies are advancing quickly: The ALIGN-ACS pilot enrolled 134 emergency-room patients in under four months, with results accepted for presentation at the TCT cardiology conference. The 500-patient HEADSTART-ACS study in Indonesia has surpassed 50% enrollment in less than three months, while a roughly 50-patient patch study is also enrolling ahead of schedule.
• Early commercial rollout is gaining traction: HeartBeam has agreements across New York, Dallas, South Florida, and Southern California, with initial orders shipped and patients being onboarded through concierge practices. Management is refining an intake-based workflow and expects order activity to increase toward the end of Q3, though current signed agreements cover only thousands of patients.
• Cost controls extend the cash runway: Q2 operating cash use declined to $3.3 million, and management expects quarterly operating cash outflow to fall below $2.5 million by Q4, with full-year 2026 operating cash outflows below $14 million. Cash, cash equivalents, and restricted cash totaled $8.8 million at June 30, extending the runway further into 2027, though a pivotal trial could increase spending.
• Platform expansion remains longer term: The company completed a working prototype of its 12-lead patch and highlighted future patent efforts involving acoustic sensing and fluid monitoring for potential heart-valve and congestive-heart-failure applications. These opportunities are not yet commercialized and add further development and regulatory uncertainty.

HeartBeam Price Performance

Shares of BEAT stock traded down $0.09 during trading hours on Friday, reaching $0.50. 1,077,036 shares of the stock were exchanged, compared to its average volume of 433,863. The business’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.98. The firm has a market capitalization of $27.72 million, a P/E ratio of -0.98 and a beta of -0.78. HeartBeam has a 12-month low of $0.48 and a 12-month high of $4.00.

Analyst Upgrades and Downgrades

BEAT has been the topic of several research reports. Wall Street Zen raised HeartBeam from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright dropped their price objective on HeartBeam from $5.50 to $2.50 and set a “buy” rating on the stock in a report on Friday, May 22nd. Maxim Group started coverage on shares of HeartBeam in a research note on Tuesday, July 14th. They set a “buy” rating and a $2.00 target price for the company. Benchmark reduced their price objective on HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating for the company in a research note on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartBeam in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC acquired a new position in shares of HeartBeam in the fourth quarter valued at approximately $26,000. Jane Street Group LLC purchased a new position in shares of HeartBeam in the fourth quarter valued at $55,000. Raymond James Financial Inc. lifted its holdings in shares of HeartBeam by 102.2% in the second quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 14,242 shares in the last quarter. Virtu Financial LLC purchased a new stake in HeartBeam in the 4th quarter valued at approximately $70,000. Finally, Insigneo Advisory Services LLC acquired a new stake in shares of HeartBeam during the fourth quarter valued at $74,000. 7.77% of the stock is owned by hedge funds and other institutional investors.

HeartBeam Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.